Literature DB >> 9849443

The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature.

M Hejna1, M Pruckmayer, M Raderer.   

Abstract

Carcinoma of the biliary tract is a rare tumour. To date, there is no therapeutic measure with curative potential apart from surgical intervention. Thus, patients with advanced, i.e. unresectable or metastatic disease, face a dismal prognosis. They present a difficult problem to clinicians as to whether to choose a strictly supportive approach or to expose patients to the side-effects of a potentially ineffective treatment. The objective of this article is to review briefly the clinical trials available in the current literature utilising non-surgical oncological treatment (radiotherapy and chemotherapy) either in patients with advanced, i.e. locally inoperable or metastatic cancer of the biliary tract or as an adjunct to surgery. From 65 studies identified, there seems to be no standard therapy for advanced biliary cancer. Despite anecdotal reports of symptomatic palliation and survival advantages, most studies involved only a small number of patients and were performed in a phase II approach. In addition, the benefit of adjuvant treatment remains largely unproven. No clear trend in favour of radiation therapy could be seen when the studies included a control group. In addition, the only randomised chemotherapeutic series seemed to suggest a benefit of treatment in advanced disease, but due to the small number of patients included, definitive evidence from large, randomised series concerning the benefit of non-surgical oncological intervention as compared with supportive care is still lacking. Patients with advanced biliary tract cancer should be offered the opportunity to participate in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9849443     DOI: 10.1016/s0959-8049(97)10166-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  36 in total

1.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.

Authors:  S A Khan; B R Davidson; R Goldin; S P Pereira; W M C Rosenberg; S D Taylor-Robinson; A V Thillainayagam; H C Thomas; M R Thursz; H Wasan
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 2.  Photodynamic therapy in the biliary tract.

Authors:  M Ortner
Journal:  Curr Gastroenterol Rep       Date:  2001-04

3.  Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Yasuo Hayashidani; Takeshi Sudo; Hiroki Ohge; Taijiro Sueda
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

Review 4.  Cholangiocarcinoma and its management.

Authors:  S A Khan; A Miras; M Pelling; S D Taylor-Robinson
Journal:  Gut       Date:  2007-12       Impact factor: 23.059

5.  Cholangiocarcinoma treatment.

Authors:  Halim Charbel; Firas H Al-Kawas
Journal:  Curr Gastroenterol Rep       Date:  2012-12

Review 6.  Photodynamic therapy for pancreatic and biliary tract carcinoma.

Authors:  Lakshmana Ayaru; Stephen G Bown; Stephen P Pereira
Journal:  Int J Gastrointest Cancer       Date:  2005

7.  Diagnosis and treatment of cholangiocarcinoma: a consensus from surgical specialists of China.

Authors:  Jian-Qiang Cai; Shou-Wang Cai; Wen-Ming Cong; Min-Shan Chen; Ping Chen; Xiao-Ping Chen; Yan-Ling Chen; Yi-Fa Chen; Chao-Liu Dai; Qiang Huang; Zhi-Yong Huang; Bo Jiang; Bin Jiang; Ke-Wei Jiang; Bo Li; Zong-Fang Li; Li-Jian Liang; Bin Liu; Hui-Chun Liu; Lian-Xin Liu; Qing-Guang Liu; Rong Liu; Ying-Bin Liu; Jian-Guo Lu; Shi-Chun Lu; Yi Lu; Yi-Lei Mao; Bin Mei; Jun Niu; Bao-Gang Peng; Xiao Qin; Yu-Dong Qiu; Guang-Yi Wang; Yao-Dong Wang; Zhi-Ming Wang; Ren-Hua Wan; Ya-Fu Wu; Bao-Cai Xing; Feng Xia; Ge-Liang Xu; Jia-Mei Yang; Xiao-Fang Yu; Yong Zeng; Yong-Yi Zeng; Bi-Xiang Zhang; Bin-Hao Zhang; Qi-Yu Zhang; Shui-Jun Zhang; Wan-Guang Zhang; Yong-Jie Zhang; Zhi-Wei Zhang; Dong Zhou; Wei-Ping Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-08-19

8.  Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas.

Authors:  Roger Kuhn; Arndt Hribaschek; Katrin Eichelmann; Stephan Rudolph; Joerg Fahlke; Karsten Ridwelski
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

9.  Long-term outcome and prognostic factors of patients with hilar cholangiocarcinoma.

Authors:  Andreas Weber; Sonja Landrock; Jochen Schneider; Manfred Stangl; Bruno Neu; Peter Born; Meinhard Classen; Thomas Rösch; Roland-M Schmid; Christian Prinz
Journal:  World J Gastroenterol       Date:  2007-03-07       Impact factor: 5.742

10.  Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.

Authors:  Nikolas Tsavaris; Christos Kosmas; Panagiotis Gouveris; Kostadinos Gennatas; Aris Polyzos; Despina Mouratidou; Heracles Tsipras; Helias Margaris; George Papastratis; Evanthia Tzima; Nikitas Papadoniou; Gavrilos Karatzas; Efstathios Papalambros
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.